Skip to main content
Veterinary Medicines

Virbagen felis RCP

Authorised
  • Felid herpesvirus 1, strain F2, Live
  • Feline calicivirus, strain F9, Live
  • Feline panleucopenia virus, strain LR 72, Live

Product identification

Medicine name:
Virbagen felis RCP
Active substance:
  • Felid herpesvirus 1, strain F2, Live
  • Feline calicivirus, strain F9, Live
  • Feline panleucopenia virus, strain LR 72, Live
Target species:
  • Cat
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Felid herpesvirus 1, strain F2, Live
    3981070.00
    tissue culture infective dose 50
    /
    1.00
    Dose
  • Feline calicivirus, strain F9, Live
    1258930.00
    tissue culture infective dose 50
    /
    1.00
    Dose
  • Feline panleucopenia virus, strain LR 72, Live
    31622.80
    tissue culture infective dose 50
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI06AD04
Authorisation status:
  • Valid
Authorised in:
  • Germany
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Virbac Tierarzneimittel GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • VIRBAC
Responsible authority:
  • Paul Ehrlich Institute
Authorisation number:
  • 149a/80
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 5/04/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."